Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cataract lens aims to sharpen vision at Arm's length

NCT ID NCT07589894

Symptom relief Sponsor: Colvard Kandavel Eye Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well a new type of lens, called Clareon TruPlus, helps people see clearly at intermediate distances (like a computer screen) after cataract surgery. About 50 adults with cataracts in both eyes will get this lens and be tested 12 weeks after surgery. The goal is to see if the lens provides good vision at arm's length without glasses, while keeping distance vision sharp.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Colvard-Kandavel Eye Center patients with bilateral cataracts

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able and willing to understand and sign informed consent. * Able and willing to complete all required study visits. * Diagnosed with age-related cataracts in both eyes (OU) * Bilateral age-related cataract scheduled for phacoemulsification in both eyes by a single surgeon. * Surgeon predicts postoperative best corrected distance visual acuity (BCDVA) of ≥ 20/25 or better with Manifest Refractive Spherical Equivalent (MRSE) ±0.50 D of plano and in each eye post-operatively. * Clear intraocular media aside from cataract. * Will receive TruPlus bilaterally * Postoperative residual astigmatism ≤ 0.75 D in both eyes. * Refractive target: Emmetropia OU * Patient groups agreeing to either Femtosecond Laser Assisted Cataract Surgery (FLACS) or Standard phaco Exclusion Criteria: * Ocular comorbidities affecting visual outcomes, including but not limited to: * Macular disease (e.g., Age-Related Macular Degeneration \[AMD\], Diabetic Macular Edema \[DME\], Epiretinal Membrane \[ERM\]). * Active ocular inflammation. * Any investigator-determined condition likely to confound postoperative visual performance. * Strabismus with or without amblyopia in either eye. * Prior anterior or posterior segment surgery, including corneal refractive procedures. * History of retinal detachment. * Degenerative retinal or visual disorders deemed clinically significant by the investigator. * Diagnosed glaucoma (of any stage, if deemed vision-impacting by investigator). * Systemic conditions that could affect healing or study outcomes (e.g., immunocompromised, connective tissue disease, clinically significant atopy, diabetes).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related cataract are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cataract senile cataract

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cataract Cataract (post-operative cataract surgery follow-up) Cataract bilateral Cataract surgery

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Colvard-Kandavel Eye Center

    Encino, California, 91316, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.